key: cord-0908483-wuh83wik authors: Wu, Daxian; Rao, Qunfang; Zhang, Wenfeng title: The natural course of COVID‐19 patients without clinical intervention date: 2021-05-19 journal: J Med Virol DOI: 10.1002/jmv.27087 sha: 3256a74bdfcc2c709753e032341fb15db208e946 doc_id: 908483 cord_uid: wuh83wik The natural course of coronavirus disease 2019 (COVID‐19) patients without clinical intervention has not yet been documented. One hundred and fifty‐eight patients from two hospitals were enrolled to identify the indicators of severe COVID‐19 and observe the natural course of COVID‐19 patients without clinical intervention. The total computed tomography (CT) score, a quantitative score based on assessment of the number, quadrant, and area of the lesions in CT, tended to perform better than assessment based only on the number or area of the lesions (p = 0.0004 and p = 0.0887, respectively). Multivariate logistic regression showed that the total CT score, chest tightness, lymphocyte, and lactate dehydrogenase (LDH) were independent factors for severe COVID‐19. For patients admitted in 2 weeks from onset to hospitalization, the frequency of severe COVID‐19 was gradually increased with the delayed hospitalization. The symptoms of fatigue, dry cough, sputum production, chest tightness, and polypnea were gradually more frequent. The levels of C‐reactive protein, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, γ‐glutamyl transpeptidase, LDH, and d‐dimer were also gradually increased, as well as the scores based on CT. Conversely, the lymphocyte count and the albumin level were gradually decreased with the delayed hospitalization. Detail turning points of the above alterations were observed after 10–14 days from onset to hospitalization. Total CT score was a simple and feasible score for identifying severe COVID‐19. COVID‐19 patients without clinical intervention deteriorated gradually during the initial 10–14 days but gradually improved thereafter. Although most COVID-19 patients experience mild symptoms, some patients deteriorate rapidly into acute respiratory distress syndrome, acute respiratory failure, and multiple organ dysfunction syndrome (MODS) . 5 Owing to the sharp distinction between severe and mild infection in patients in terms of the in-hospital mortality rate, 10 identification of predictive indicators for critically ill patients is necessary to effectively prioritize resources for these patients. This is especially true for regions experiencing medical resource shortages. The natural course involves in the whole process of the disease from occurrence, development to outcome without any clinical intervention. Profile of the natural course of COVID-19 assists clinicians makes an optimal medical decision at different time points. Usually, symptoms were onset after 3-7 days of incubation phase. The estimated time from the first symptom to pneumonia confirmed by radiology was 5 days. Acute respiratory distress syndrome, the peak of infection, was presented at 9.5-10.5 days after symptoms onset, and most patients were admitted in the intensive care unit at this time. 6, 11, 12 However, the clinical course described above was COVID-19 was confirmed by detectable nucleic acid by real-time reverse transcriptase-polymerase chain reaction assay using nasal and pharyngeal swab specimens. Only confirmed patients were included in the analysis. Patients who taken drugs (antibiotics, antipyretics, etc.) or received nursing care under the guidance of personnel with professional medical background before their admission were excluded. Severe COVID-19 at admission was defined according to the clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. 13 Patients who did not meet the criteria of severe COVID-19 were defined as mild COVID-19. It was considered as symptom onset when the patient has any one of the symptoms including fever, dry cough, fatigue, sputum production, chills, myalgia, chest tightness, polypnea, headache and dizziness, sore throat, rhinorrhea and rhinobyon, and diarrhea. Bacterial infection was diagnosed based on the previous study. 14 Briefly, it was considered if the positive bacterial culture of blood, sputum, urine, or other tissues was obtained. Additionally, it was also considered if any one of items (1)-(3) and item (4) were met: (1) purulent sputum and newly occurred respiratory symptoms or aggravation of original respiratory symptoms; (2) white blood cell count > 10 × 10 9 /L; (3) procalcitonin > 0.1 ng/ml; (4) chest radiography showed bacterial pneumonia. Liver injury was defined as a total bilirubin (TBil) level of ≥21 μmol/L or an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level of ≥50 U/L. Brain and kidney injuries were characterized by a Glasgow coma scale of ≤14 and a serum creatinine level of ≥105 μmol/L, respectively. Coagulation injuries were characterized by a platelet count of ≤100 × 10 9 /L, the prolongation of the prothrombin time (PT) or thrombin time (TT) by ≥3 s, or the prolongation of activated partial thromboplastin time (APTT) by ≥10 s. Circulation injury was characterized by a mean arterial pressure of less than 70 mmHg or vasoactive agents were used. Muscle injury was characterized by creatine kinase levels of ≥200 U/L. All patients received comprehensive medical treatments during hospitalization, including bed rest, water/electrolyte balance, nutritional support, and antiviral therapy with interferon-α, lopinavir and ritonavir, ribavirin, or arbidol. For patients with decreased PaO 2 or SpO 2 , oxygen therapy with a nasal catheter or venturi mask was supplied. For patients with bacterial infection, empirical antibiotic therapy was executed immediately and then adjusted based on the results of microbial culture. Glucocorticoid, immunoglobulin, mechanical ventilation, and/or vasoactive drugs were used as necessary for severe patients. COVID-19 patients who met all the following items could be discharged from hospital: (1) normal body temperature persisted more than 3 days; (2) the symptoms, especially respiratory symptoms, improved significantly; (3) the acute exudative lesions in pulmonary imaging were significantly improved; (4) at least two nucleic acid tests for SARS-CoV-2 were negative. Data on the demography, epidemiology, symptoms, and signs, as well as on laboratory parameters were collected from the patients' medical records or the hospital database using a predesigned datasheet. Laboratory parameters detected using fasting blood samples at patients' admission were adopted. Detail detected laboratory parameters included C-reactive protein, white blood cell count, lymphocyte count, neutrophils count, red blood cell count, hemoglobin, platelets, albumin, ALT, AST, TBil, direct bilirubin (DBil), γ-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), creatinine, urea nitrogen, creatine kinase, PT, TT, APTT, and D-dimer. All detections were performed routinely at the Central Clinical Laboratory of the hospital where the patients were enrolled. The number, quadrant, and area of lesions in CT were scored using a simple method to assess the severity of COVID-19. As shown in Table 1 , the lesion number was scored zero for patients without lesion, and scored one, two, and three for patients with one, two, and three lesion(s), respectively. The lesion number was scored four for patients with four or more lesions. The quadrant was scored zero for patients without lesion and scored one, two, three, and four when lesion(s) occupied one, two, three, and four CT quadrants, respectively. The area was scored zero for patients without lesion and scored one, two, and three when the area of maximum lesion was less than 10, 25, and 100 cm 2 , respectively. The area was scored four when the area of maximum lesion was 100 cm 2 or more. The total CT score was calculated as the sum of the lesion, quadrant, and area scores. Statistical Package for the Social Sciences (SPSS, vers. 25.0; SPSS Inc.) was used to perform statistical analysis. Continuous data are presented as the mean ± standard deviations or medians with percentiles (P25-P75) and compared using Student's t-test or the Mann-Whitney U test as appropriate. The rank correlation was analyzed using Spearman's method. Categorical data are presented as numbers (%) and compared either by the χ 2 or Fisher's tests. Independent risk factors for severe COVID-19 were identified by multivariate logistic regression according to the forward Wald method, with entry and removal probabilities of 0.05 and 0.10, respectively. The area under the receiver operating characteristic curves (AUROCs) was compared using a Z-test with Delong's method. As shown in Table 2 , the mean age of COVID-19 patients was 50.84 ± 16.38, and most patients (85.3%) had a clear exposure history. Sixty (38.0%) patients had one or more comorbidities, and the most frequent comorbidities were hypertension (15.2%), diabetes (12.7%), and bacterial infection (10.8%). The most frequent symptom was fever (85.3%), followed by dry cough (43.7%) and chest tightness (34.8%). Rare symptoms included diarrhea (6.3%) and rhinorrhea/ rhinobyon (5.7%). The most frequent extrapulmonary organ injury was liver injury (24.1%), followed by the muscle (7.6%), kidney (6.3%), and coagulation (5.7%) injuries. Circulation (3.8%) and cerebral (1.3%) injuries are rare in COVID-19 patients. The age of severe patients was significantly higher than that of mild patients (55.67 ± 18.36 vs. 48.92 ± 15.19; p = 0.021). The comorbidities were more frequent in severe patients than mild patients (51.7% vs. 32.7%; p = 0.033). Among the comorbidities, the frequency of bacterial infection was higher in severe patients than mild patients (20.0% vs. 7.1%; p = 0.023). No significant differences of other comorbidities between severe and mild patients were observed. Symptomatically, sputum production, chest tightness, and polypnea are more common in severe patients than mild patients (all p < 0.05). No other symptomatic difference between severe and mild patients was observed. The levels of C-reactive protein, neutrophils count, DBil, GGT, LDH, creatine kinase, PT, and D-dimer were significantly higher, but lymphocyte count and albumin level were significantly lower in severe patients compared to mild patients ( Table 2 ). The frequency of liver, muscle, and circulation injuries in severe patients was significantly higher than those in mild patients. Both two cases with cerebral injury were severe patients. The AUROC of the total CT score for identifying severe COVID-19 was 0.764, with a sensitivity of 0.733 and a specificity of 0.717 at an optimal cut-off value of 9 ( Table 3 ). The total CT score performed better than the number score and tended to provide better identification of severe COVID-19 than the area score (p = 0.0004 and p = 0.0887, respectively; Figure 1 ). Next, we evaluated the performance of the total CT score in combination with clinical parameters at admission to identify the severe COVID-19. Univariate and multivariate logistic regression analysis showed that the total CT score, together with chest tightness, lymphocyte count, and LDH were independent indicators for severe COVID-19 (Table 2) . Among them, lymphocyte count was the only protective factor for severe COVID-19. The present study first observed the alteration trends of clinical characteristics with delayed hospitalization in 2 weeks, as shown in Table 4 , the frequency of severe COVID-19 patients was gradually Notably, the total score and area score based on CT were gradually increased in 10 days but gradually decreased after 10 days from onset to hospitalization. The number CT score and quadrant CT score gradually increased in 14 days but gradually decreased after 14 days ( Figure 2D ). As shown in Table 4 , the frequency of severe COVID-19 patients admitted after 14 days was significantly lower than those who admitted at 7-14 days. The polypnea was more frequent in patients admitted after 14 days than those admitted at 7-14 days. The levels of C-reactive protein, AST, and LDH were significantly lower in patients admitted after 14 days than those who admitted at 7-14 days, as well as the total CT, number CT, quadrant CT, and area CT scores. The count of lymphocytes of patients admitted after 14 days was significantly higher than that in patients admitted at 7-14 days. Those alterations suggested that 2 weeks after disease onset is a turning point of the clinical course of COVID-19. The clinical manifestations of COVID-19 patients have been found to vary greatly, from asymptomatic carriers to patients with respiratory failure, and even MODS. Consistent with previous reports, 15 the most frequent symptoms of COVID-19 patients were fever, dry cough, and chest tightness, while diarrhea was rare. Toxicosis symptoms, such as fatigue and myalgia, were also common in patients with COVID-19. Upper respiratory tract symptoms, such as rhinorrhea, sneezing, and sore throat, were also found to occur, which were clinical features that were unique from MERS and SARS. 7, 8 Additionally, the present study demonstrated that the liver was the most frequently injured extrapulmonary organ, with an incidence rate that was much higher than that of other organs, suggesting that coronavirus may also be a hepatotropic virus. The underlying mechanism of COVID-19 may due to the ubiquitous distribution of angiotensinconverting enzyme 2, which is the main viral entry receptor. 16 However, further experiments using cell and animal models will be required to confirm these findings. CT plays a very important role in the early diagnosis and efficacy evaluation of COVID-19 due to its high sensitivity. 17 Hence, it was speculated that the inflammation of COVID-19 was initiated from disease onset and peaked at 14 days, but inhibited at the third week of the clinical course. Conversely, the lymphocyte count decreased gradually in the initial 14 days but began to gradually increase 14 days after disease onset, suggesting that the recovery of the lymphatic system was also initiated after 14 days. Most notably, the total score and area score based on CT were gradually increased in 10 days but gradually decreased after 10 days from onset to hospitalization, as well as the results of LDH, GGT, and AST levels were observed, which suggested that lung lesions began to assimilate and liver function began to recover 10 days after disease onset. These results In conclusion, this study provided a simple and feasible scoring approach based on CT images to assess the severity of COVID-19 and identified four independent indicators for severe COVID-19. Moreover, this study demonstrated COVID-19 patients without clinical intervention deteriorated gradually during the initial 10-14 days, but gradually improved thereafter. We believe that our findings provide an insight into improving the management of COVID-19 and the allocation of limited medical resources. The authors declare that there are no conflict of interests. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding A novel coronavirus from patients with pneumonia in China COVID-19 and cancer: from basic mechanisms to vaccine development using nanotechnology Clinical characteristics of coronavirus disease 2019 in China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan A major outbreak of severe acute respiratory syndrome in Hong Kong Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical course and mortality risk of severe COVID-19 Epidemiology of SARS-CoV-2 COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19 The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak COVID-19 and liver disease Coronavirus disease 2019 (COVID-19): a perspective from China Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019 Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19 Dynamic CT assessment of disease change and prognosis of patients with moderate COVID-19 pneumonia